• Profile

LIfeSTyle vs Ezetimibe plus lifestyle in patients with biopsy-proven Non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial

Nutrition, Metabolism & Cardiovascular Diseases Feb 03, 2022

No improvement in the histology of non-alcoholic steatohepatitis (NASH) was observed in patients who underwent ezetimibe treatment (a lipid lowering drug able to promote cholesterol efflux from the liver) plus lifestyle and dietary modification, vs those with lifestyle and dietary modification alone.

  • In a phase IV 52 weeks double blind parallel randomized controlled trial (LISTEN trial), researchers assessed the impact of ezetimibe plus lifestyle and dietary intervention (eze) vs lifestyle and dietary intervention alone (placebo) on progression and complications of NASH evaluated by liver histology.

  • A total of 40 NASH patients were randomized and received a follow-up of 52 weeks, when they underwent a second liver biopsy; 30 patients completed the study.

  • Main composite endpoint (EP) was based on the histological improvement in the severity of NASH.

  • No improvement in the primary EP was achieved with eze treatment vs placebo, with odds ratio of 1.029 (0.18-6.38).

  • Treatment emergent adverse events were not more prevalent in the treatment arm.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen